person
as of 2026-07-01Carol A Tamminga, MD
ORCID 0000-0002-6366-5697
at a glance
Roles: Principal Investigator, Author
KOL signal score 9
3 publications · 2 high-value
Cross-drug reach: 2 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
University of Texas Southwestern Medical Center
Roles
Principal Investigator, Author
KOL signal
9
Publications
3 (2 high-value)
Trial investigator
no
Publishes on
2 drugs
Trials led
3
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
NCT00690235Phase 4Completed
Study to Demonstrate Cognitive Enhancing Effects of BF2.649
NCT00690274Phase 2Completed
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
NCT00628394Phase 4Completed
Publications & congress
3
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2024 · high-value
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
JAMA psychiatry · 2020 · high-value
Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on